Clincosm LogoSign in Get a demo

The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients

Sponsor
Biotec Pharmacon ASA (Industry)
Overall Status
Completed
CT.gov ID
NCT00289003
Collaborator
(none)
40
Enrollment
3
Locations
33
Duration (Months)
13.3
Patients Per Site
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy.

Hypothesis: Soluble beta-1,3/1,6-glucan will through its immunomodulating activities prevent oral mucositis

Condition or Disease Intervention/Treatment Phase
  • Drug: Soluble beta-1,3/1,6-glucan
 Phase 2

Detailed Description

Oral mucositis is defined as inflammation and ulceration of the mucous membranes of the mouth. The condition is very painful and might put the patient at risk of serious systemic infections and is a common dose-limiting toxicity of chemotherapy and radiotherapy. The present treatment of mucositis is primarily supportive; strong analgesics in addition to oral hygiene. Prophylactic antibiotics have been used and many topical agents are available to palliate mucositis, but no standard therapy has been accepted.

Comparison: Methyl cellulose has been chosen as placebo due to its close resemblance to soluble beta-1,3/1,6-glucan in terms of general appearance and viscosity. Methyl cellulose is a viscous solution which might form a mucosal barrier. Physical barriers are considered having a protective function in oral mucositis, and methyl cellulose might be considered as an active control.

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
An Exploratory, Randomised, Parallel Group Study, Comparing the Protective Effect of Soluble Beta-1,3/1,6-Glucan or Placebo in Oral Mucositis in Head and Neck Cancer Patients Receiving Radiation Therapy or Chemoradiotherapy
Study Start Date :
Oct 1, 2003
Study Completion Date :
Jul 1, 2006

Outcome Measures

Primary Outcome Measures

  1. To assess actual grade of mucositis upon completion of radiotherapy or chemoradiotherapy and after prophylactic treatment with soluble beta-1,3/1,6-glucan or placebo. []

Secondary Outcome Measures

  1. To assess proportions of patients avoiding grade 2 or higher oral mucositis after treatment with soluble beta-1,3/1,6-glucan or placebo []

  2. To assess time before first sign of oral mucositis []

  3. To evaluate impact of toxicities like patients' pain and swallowing difficulty []

  4. To assess the safety of the investigational product []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Patients undergoing radiotherapy or chemoradiotherapy for histologically confirmed squamous cell carcinoma of oral cavity or oropharynx (1.8-2.0 Gy/day; 5 days per week, totally 59.4-70 Gy).

  • Normal mucosa at baseline (i.e. Common Toxicity Criteria (CTC) grade 0)

  • = 18 years of age

  • Women of childbearing potential must use an adequate contraceptive method and have a negative pregnancy test

  • Written informed consent

Exclusion Criteria:

  • Patients who will receive hyperfractionated or accelerated radiotherapy

  • History of malignancies within the past five years other than non-melanomatous skin cancers (with the exception of squamous cell carcinoma of the skin) or carcinoma in situ of the cervix

  • Previous neoplasm in the head and neck area, whether malignant or not

  • Previous radiation therapy for head and neck cancer

  • If wound from curative surgery have not healed

  • Patients expected to receive agents that would interfere with the investigator's ability to assess changes in the appearance of the mucositis during the study

  • Use of radiosensitizers

  • History or clinical evidence of active significant acute or chronic diseases that may compromise the ability to evaluate or interpret the effects of the study treatment on mucositis

  • Evidence of distant metastatic disease

  • Expected survival of less than 12 months

  • grade 3 performance status (WHO grading)

  • Granulocyte count < 2.000/mm3 and platelet count < 100,000/mm3

  • Serum creatinine >= 150 micromol/L

  • Total bilirubin >= 36 micromol/L, AST > 3 times the upper normal limit

  • Any subject who, in the opinion of the investigator, is unlikely to comply with the study procedures, or is unlikely to complete the study due to different reasons like e.g. language barriers or mental incapacity

  • Participation in a clinical trial in the last 30 days Receipt of any investigational product within 30 days prior to this trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical Centre Bonn, Clinic for Radiotherapy and Radiological Oncology Bonn Germany 53119
2 Evangelisches Krankenhaus Düsseldorf Germany 40217
3 Royal Marsden Hospital, Head and Neck Unit London United Kingdom SW3 6JJ

Sponsors and Collaborators

  • Biotec Pharmacon ASA

Investigators

  • Principal Investigator: Christopher M Nutting, Dr.med., Royal Marsden NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00289003
Other Study ID Numbers:
  • SMR-907-SBG-1-02-HN
First Posted:
Feb 9, 2006
Last Update Posted:
Jan 17, 2007
Last Verified:
May 1, 2006
Additional relevant MeSH terms:
Head and Neck Neoplasms
Mucositis
Stomatitis

Study Results

No Results Posted as of Jan 17, 2007